Anzeige
Erschienen in:
13.09.2019 | Letter
Diagnostic criteria should be considered when reviewing the effect of diabetes prevention studies
Erschienen in: Diabetologia | Ausgabe 11/2019
Einloggen, um Zugang zu erhaltenExcerpt
To the Editor: Nathan and colleagues recently published a review of diabetes prevention trials, specifically looking at their long-term effects on reducing the diabetes-related vascular complications [1]. Data from nine diabetes prevention studies were thoroughly and comprehensively analysed to investigate the association of diabetes prevention with microvascular or cardiovascular complications. The majority of participants enrolled in the nine studies had either impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) or both. We found that in Table 1 of their review [1], Nathan et al included details of the specific diagnostic criterion for IFG, which was a fasting plasma glucose (FPG) level of 5.3–6.9 mmol/l in the Diabetes Prevention Program (DPP) trial, but no details were given for other trials. In fact, the definitions given for IFG or IGT in terms of the range of FPG were inconsistent across studies.
Table 1
Description of major diabetes prevention studies reporting long-term complications
